Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures

The exceptional in vitro potency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into an in vivo effect in proof-of-concept clinical trials. Although the 50% effective concentration (EC(50)) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it...

Full description

Saved in:
Bibliographic Details
Main Authors: Lemm, Julie A., Leet, John E., O'Boyle, Donald R., Romine, Jeffrey L., Huang, Xiaohua Stella, Schroeder, Daniel R., Alberts, Jeffrey, Cantone, Joseph L., Sun, Jin-Hua, Nower, Peter T., Martin, Scott W., Serrano-Wu, Michael H., Meanwell, Nicholas A., Snyder, Lawrence B., Gao, Min
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2011
Subjects:
Antiviral Agents
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147613/
https://ncbi.nlm.nih.gov/pubmed/21576451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00146-11
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items